A Phase 3 Randomized Controlled Study of Metronomic Capecitabine Combined With Aromatase Inhibitor Versus Aromatase Inhibitor Alone for First Line Treatment in Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Capecitabine (Primary) ; Aromatase inhibitors
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms MECCA
- 30 May 2017 Planned End Date changed from 1 May 2021 to 1 May 2023.
- 30 May 2017 Planned primary completion date changed from 1 May 2019 to 1 May 2021.
- 30 May 2017 Planned initiation date changed from 1 Jun 2016 to 1 Sep 2017.